New Treatments
Transforming TB Treatment
TB Alliance is leading the global effort to develop faster, simpler, and more effective cures for all forms of TB.
Learn More:

TB Alliance at the 2026 Union Conference
Join TB Alliance and partners at the 57th Union World Conference on Lung Health, taking place in Rio de Janiero from 17 – 20 November 2026. Find out more about our presentations and events at the conference.
Meeting with Global TB Stakeholders
Our 2026 Global TB Stakeholders Meeting brought together partners, advocates, and global health leaders with a focus on the promise of and significant progress in establishing a pathway to TB Alliance’s 1×1 vision for the future of TB treatment – one-month treatment for active TB and one-day treatment for latent TB infection.


The Latest from TB Alliance
Impact of BPaL/M: Shorter Care. More Lives Saved. Lower Costs.
Findings from Johns Hopkins University research show that BPaL/M is on track to save 191k lives and US$1.29B by 2034—while boosting treatment completion and success. Read more.
TB By The Numbers

REACHING THOSE IN NEED
Delivering Treatments
TB Alliance’s mission is not complete until new drugs are in the hands of those who need them.
More News:
TRANSFORMING TB TREATMENT
Charting the Course
We’ve all come to know the impact of infectious diseases, but we also know the power of science.
More News:

TB Alliance manages the largest pipeline of new TB drugs in history.
International Cooperation Aims to Expand Access to Tuberculosis Medicines through Brazil’s Public Health System
Fiocruz, TB Alliance and Viatris sign Memorandum of Understanding to strengthen domestic manufacturing capacity for…
TB Alliance Appoints Jerome H. Kim, MD as next President and Chief Executive Officer
New CEO to begin in April 2027, leading TB Alliance’s next chapter in research, innovation,…
Union Conference to Feature Promising Findings from TB Alliance on Novel TB Drug Candidate Sorfequiline and the BPaL DR-TB Regimen
Data to be presented supports sorfequiline’s long-term outcomes data from the Phase 2 study NC-009,…

